Featured Research

from universities, journals, and other organizations

Molecular 'Foreman' Discovered For Brain Wiring

Date:
November 24, 2007
Source:
Cell Press
Summary:
Researchers have identified a master regulatory molecule that is responsible for triggering the remodeling of neuronal connections that is critical for learning. Malfunctioning of the connection-remodeling machinery that they identified may also play a role in mental retardation, schizophrenia, and drug addiction. Thus, said the researchers, knowledge of the machinery could lead to insights into those disorders.

When you meet your boss's husband, Harvey, at the office holiday party, then bump into him an hour later over the onion dip, will you remember his name? Yes, thanks to a nifty protein in your brain called kalirin-7.

Researchers have identified a master regulatory molecule that is responsible for triggering the remodeling of neuronal connections that is critical for learning.

Malfunctioning of the connection-remodeling machinery that they identified may also play a role in mental retardation, schizophrenia, and drug addiction. Thus, said the researchers, knowledge of the machinery could lead to insights into those disorders.

Peter Penzes and colleagues published their findings in the journal Neuron. In their experiments, the researchers sought to understand the biological machinery controlling the enlargement of mushroom-like structures called dendritic spines on neurons. Such spines are the receiving stations for neurotransmitters--signaling chemicals that one neuron launches to trigger a nerve impulse in its neighbor. During learning, these spines strengthen signaling between neurons during the process of laying down memory pathways in the brain.

Spine structure can also be involved in neurological disorders. Researchers have found abnormal dendritic spines in certain types of mental retardation, including autism spectrum disorders, as well as schizophrenia and drug addiction.

Specifically, Penzes and colleagues sought to discover whether a molecule called kalirin-7 plays a role in spine enlargement in mature neurons when they undergo a learning-related strengthening called long-term potentiation (LTP).

The researchers theorized that kalirin-7 might be a key regulator of spine development because it is found in high concentration in the spines of mature neurons. Also, kalirin-7 was known to play a role in the remodeling of the structural beams and studs of the cell, called the cytoskeleton.

The researchers' experiments with cultured neurons revealed that activation of neurons during LTP does indeed trigger kalirin-7 to turn on the machinery for remodeling spines, causing spines to become enlarged.

What's more, the researchers found that kalirin-7 also regulates the other major process necessary for strengthening neuronal signaling connections. Kalirin-7 controls the number of neurotransmitter-receiving stations, called receptors, that festoon the surface of dendritic spines. The number of these receptors determines the strength of signaling connections between neurons.

The researchers concluded that their findings "strongly suggest that kalirin-7 may be an important regulator of the experience-dependent modifications of forebrain circuits during postnatal development and may play an important role in learning and memory."

They also pointed out that altered spine structures "have been associated with mental retardation, neuropsychiatric disorders, and drug addiction. Specifically, aberrant spine morphology in forebrain occurs in many types of mental retardation, including fragile-X and autism spectrum disorders." Similarly, they noted, studies of schizophrenics have also revealed such alteration of dendritic spines, as well as evidence of defects in the kalirin-7 pathway.

"Therefore, our results may suggest potential strategies for treatments of these neurodevelopmental and psychiatric diseases," they wrote.

This research was published November 21, 2007. The researchers include Zhong Xie, Deepak P. Srivastava, Huzefa Photowala, Li Kai, Michael E. Cahill, Kevin M. Woolfrey, Cassandra Y. Shum, D. James Surmeier, and Peter Penzes, of the Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Molecular 'Foreman' Discovered For Brain Wiring." ScienceDaily. ScienceDaily, 24 November 2007. <www.sciencedaily.com/releases/2007/11/071121145025.htm>.
Cell Press. (2007, November 24). Molecular 'Foreman' Discovered For Brain Wiring. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/11/071121145025.htm
Cell Press. "Molecular 'Foreman' Discovered For Brain Wiring." ScienceDaily. www.sciencedaily.com/releases/2007/11/071121145025.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins